Allogenic γδ T cell and tumor cell fused vaccine for enhanced immunotherapeutic efficacy of osteosarcoma
Allogenic γδ T cell and tumor cell fused vaccine for enhanced immunotherapeutic efficacy of osteosarcoma
复制标题
同种异体γδ T细胞和肿瘤细胞融合疫苗增强骨肉瘤免疫治疗效果
DOI：
10.1016/j.jbo.2018.100214
复制
发表时间：
2020-04-01
影响因子：
3.4
通讯作者：
Tao，Huimin
中科院分区：
文献类型：
--
作者：
Wang，Yitian;Zhu，Jian;Tao，Huimin
人类γδT细胞通过有效的肿瘤杀伤活性显示出其在癌症免疫方面的潜力。此外，它们还以其抗原呈递能力而闻名。如何提高γδT细胞作为细胞疫苗的免疫治疗效果仍然是一个巨大的挑战。在此，我们探索人γδ T细胞和肿瘤细胞融合疫苗以增强骨肉瘤的免疫治疗效果。融合细胞疫苗是通过人γδT细胞与失活骨肉瘤Saos-2细胞的化学融合制备的。通过显微镜观察证实了融合过程，流式细胞术分析进一步验证了融合细胞的抗原呈递功能。此外，通过细胞毒性测定和细胞因子释放检测验证了融合细胞的免疫治疗潜力。我们的研究为骨肉瘤患者提供了新的免疫治疗策略，值得在不久的将来进一步实践。
Human γδ T cells have displayed their potential in cancer immunity through efficient tumor killing activities. Besides, they are also known for their capacity of antigen presentation. How to improve γδ T cells' immunotherapeutic effect as the cell vaccine is still a great challenge. Herein, we explore the human γδ T cells and tumor cell fused vaccine for enhanced immunotherapeutic efficacy of osteosarcoma. The fusion cell vaccine was prepared by chemical fusion between human γδ T cells and inactive osteosarcoma Saos-2 cells. The fusion process was confirmed by microscopy observation, and flow cytometry analysis further validated the antigen presenting functions of the fusion cells. Moreover, the immunotherapeutic potential of the fusion cells was then verifiedviacytotoxicity assay and cytokine release detection. Our study provided novel immunotherapeutic strategy for patients with osteosarcoma, which merits further practice in the near future.